Accès ouvert
2026
article
OpenAlex
Naveen Rehman, Emily C. Zabor, Aastha Dhakal, Bridget Adcock et autres
Advances in immunotherapy (IT) and targeted therapy have transformed treatment for stage IV non-squamous non-small cell lung cancer (NS-NSCLC). However, real-world data comparing modern regimens to previous standards remains limited. Herein, we aim to determine whether survival outcomes have improved with contemporary …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy et autres
Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%-30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG. Historical estimates suggest that thymoma associated MG …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Mohammadhadi Khorrami, Ameish Govindarajan, Juyoung Lee, Sawyer Bawek et autres
8020 Background: Subsequent treatment for extensive-stage small cell lung cancer (ES-SCLC) following platinum-etoposide chemotherapy +/- an immune checkpoint inhibitor was historically limited to alternative forms of chemotherapy with relatively poor clinical outcomes. Bispecific delta-like ligand 3 (DLL3)-targeting T-cell engagers, such as tarlatamab, …
us
(code pays fourni par la source)
2026
article
OpenAlex
Lukas Delasos, Khaled Aref Hassan
The treatment landscape of non–small cell lung cancer (NSCLC) has advanced considerably in the past two decades, driven largely by molecular profiling and the development of targeted therapies. Among oncogenic drivers, mutations in the epidermal growth factor receptor (EGFR) have proven to …
us
(code pays fourni par la source)
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Baseline Patient Characteristics – Cohort A
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior …
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Baseline Patient Characteristics – Overall Cohort
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
Accès ouvert
2025
supplementary-materials
OpenAlex
Marcelo Vailati Negrao, Haniel Alves Araújo, Giuseppe Lamberti, Alissa Jamie Cooper et autres
Multivariable analysis - overall survival